In a patient on dabigatran (Pradaxa) with hemoptysis who cannot receive IV contrast, how should the bleeding be managed and the source evaluated?

Management of Hemoptysis in a Patient on Dabigatran Without IV Contrast

Immediately administer idarucizumab (Praxbind) 5 g IV to reverse dabigatran's anticoagulant effect in this life-threatening bleeding scenario, then proceed with non-contrast CT chest to evaluate the source of hemoptysis. 1

Immediate Reversal Strategy

Idarucizumab is the specific antidote for dabigatran and should be your first-line agent for life-threatening bleeding. 1

• Administer 5 g IV (two 2.5 g/50 mL vials) without dose adjustment for age, renal function, or dabigatran plasma concentration 1
• Idarucizumab achieves 100% median reversal of dabigatran's anticoagulant effect within minutes, as measured by diluted thrombin time and ecarin clotting time 1
• The antidote binds dabigatran with 300 times greater affinity than dabigatran binds to thrombin, immediately neutralizing its anticoagulant effects 1

If idarucizumab is unavailable, use non-activated prothrombin complex concentrate (PCC) 50 U/kg IV or activated PCC (FEIBA) 30-50 U/kg IV as second-line agents, though their efficacy is not formally established 1, 2

Supportive Hemostatic Measures

Implement these measures simultaneously with reversal:

• Omit the next scheduled dose of dabigatran 2
• Administer tranexamic acid 1 g IV for significant bleeding 2
• Maintain renal perfusion and urine output to enhance dabigatran excretion (80% renal elimination) 2, 3
• Consider hemodialysis if idarucizumab unavailable and patient has renal impairment, as dabigatran exhibits low protein binding and is dialyzable 1, 2
• Administer activated charcoal with sorbitol if dabigatran was taken within 2 hours 1, 2

Diagnostic Evaluation Without IV Contrast

Proceed with non-contrast CT chest immediately after reversal to identify the bleeding source: 4

• Non-contrast CT can identify masses, infiltrates, bronchiectasis, cavitary lesions, and active hemorrhage
• Consider CT pulmonary angiography (CTPA) once hemostasis is restored and dabigatran is reversed, as the contrast itself is not contraindicated—the issue is performing imaging while actively anticoagulated 4
• Bronchoscopy can be performed after reversal for both diagnosis and potential therapeutic intervention 1

Laboratory Monitoring

Check these coagulation parameters to assess dabigatran effect:

• Activated partial thromboplastin time (aPTT) provides qualitative assessment of dabigatran activity 2, 3
• Thrombin time (TT) is highly sensitive—a normal TT excludes significant dabigatran levels 1, 2
• Prothrombin time/INR is unreliable for dabigatran and should NOT be used 2, 3
• If available, direct thrombin inhibitor (DTI) assays provide quantitative dabigatran plasma concentration 1, 2

Critical Pitfalls to Avoid

Do not delay reversal while waiting for laboratory results in life-threatening bleeding. 1

• The RE-VERSE-AD study demonstrated that idarucizumab can be given empirically without knowing dabigatran levels 1
• A second 5 g dose of idarucizumab may be needed if bleeding recurs or coagulation parameters re-prolong, as dabigatran concentrations can reappear up to 24 hours after initial reversal 1

Do not use fresh frozen plasma (FFP)—it will not reverse dabigatran's direct thrombin inhibition. 5

Do not use recombinant factor VIIa as first-line therapy—it is no longer recommended due to uncertain benefit/risk ratio. 1

Post-Reversal Management

After achieving hemostasis:

• Investigate risk factors that contributed to bleeding: renal insufficiency (dabigatran contraindicated if CrCl <30 mL/min), concomitant antiplatelet agents, advanced age, fall risk 6
• Reassess anticoagulation indication and consider alternative agents if dabigatran contributed to bleeding 1
• Monitor for thrombotic complications—the RE-VERSE-AD study reported 6.3% thrombotic events at 90 days after reversal 1